Hospital & Healthcare Services · Founded 1990 · www.cmmh.in · BSE 523489 · · ISIN INE889F01017
No Notes Added Yet
Business
Chennai Meenakshi Multispeciality Hospital Ltd. operates a hospital facility in India, providing a comprehensive range of medical services. Its core business model revolves around delivering tertiary and secondary healthcare across multiple specialities. The company generates revenue by charging patients directly or through insurance providers for consultations, diagnostic tests, medical procedures (including surgeries), inpatient care, emergency services, and pharmacy sales. As a multispeciality hospital, it aims to cater to diverse medical needs under one roof.
Revenue Mix
While specific revenue segmentation is not publicly available, a multispeciality hospital typically derives its revenue from:
Inpatient Services: This generally forms the largest segment, including room charges, nursing care, surgical fees, and critical care services.
Outpatient Services: Consultations, minor procedures, and day care services.
Diagnostic Services: Radiology (X-rays, MRI, CT scans) and pathology (blood tests, biopsies).
Pharmacy & Other Allied Services: Sale of medicines and medical consumables.
Emergency & Trauma Care: Revenue from urgent medical interventions.
Industry
The Indian hospital and healthcare services industry is large, fragmented, and growing rapidly, characterized by a mix of large corporate hospital chains, regional multispeciality hospitals, and standalone single-speciality clinics. CMM HOSPITAL, as indicated by its name, likely operates a significant facility in Chennai, suggesting a regional focus. It would compete with both major national corporate chains (like Apollo, Fortis, MGM Healthcare which have a strong presence in Chennai) and other standalone or smaller chain hospitals in the region, differentiating itself through doctor talent, service quality, and local brand recognition.
MOAT
For a regional multispeciality hospital, competitive advantages typically include:
Local Brand Reputation & Trust: A long-standing presence and positive patient experiences can build significant trust within the local community.
Doctor Talent & Network: The ability to attract and retain highly skilled and renowned doctors in various specialities is a major draw for patients.
Strategic Location: Proximity and accessibility for a large patient base in Chennai.
Specialized Services: Offering niche or high-end medical procedures not widely available can create a unique selling proposition.
However, without specific details, it is difficult to ascertain the depth of these advantages against larger, more resourced competitors.
Growth Drivers
Key factors that can drive growth for CMM HOSPITAL over the next 3-5 years include:
Increasing Healthcare Expenditure: Rising disposable incomes and awareness driving demand for quality healthcare.
Aging Population & Lifestyle Diseases: Growing prevalence of chronic and lifestyle-related ailments requiring specialized care.
Expanding Health Insurance Penetration: More individuals covered by insurance, increasing affordability and access to private healthcare.
Medical Tourism: Chennai is a hub for medical tourism, which could attract patients from other countries or regions.
Technological Advancements: Adoption of new medical technologies and procedures to enhance service offerings and outcomes.
Capacity Expansion: Adding more beds, operating theatres, or diagnostic facilities to cater to higher patient volumes.
Risks
Intense Competition: Significant competition from established large corporate chains and numerous smaller hospitals in Chennai, leading to pricing pressure and challenges in talent acquisition.
Doctor Retention: Difficulty in attracting and retaining highly skilled medical professionals, who are critical to patient outcomes and hospital reputation.
Regulatory & Pricing Risks: Government regulations on treatment costs, drug pricing, or quality standards can impact profitability.
High Capital Expenditure: Hospitals require continuous investment in infrastructure, medical equipment, and technology, leading to significant capital outlay.
Medical Malpractice & Litigation Risks: Exposure to legal challenges related to medical errors or adverse patient outcomes.
Public Health Crises: Events like pandemics can strain hospital resources, impact non-essential treatments, and affect patient footfall.
Geographic Concentration: Dependence on a single or limited number of facilities in one city exposes the company to local economic and competitive dynamics.
Management & Ownership
As is common with many Indian companies, it is likely that CMM HOSPITAL is promoter-driven, with the founding family or group holding a significant ownership stake and being actively involved in the management. Details on specific individuals, their experience, or the broader ownership structure (e.g., institutional holdings) are not available.
Outlook
The outlook for CMM HOSPITAL is shaped by the favorable long-term demand for healthcare in India, driven by demographic shifts and increasing affordability. A well-established regional multispeciality hospital in a key city like Chennai stands to benefit from these tailwinds, potentially leveraging its local brand, doctor network, and quality of care to attract patients. However, the company operates in a highly competitive and capital-intensive industry. Its ability to navigate intense competition from larger, well-funded hospital chains, attract and retain top medical talent, manage rising operational costs, and adapt to evolving regulatory environments will be crucial. Sustained operational efficiency, strategic investments in technology, and maintaining patient trust will be key determinants of its future performance.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 10 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 9 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 10 | 9 | 8 | 9 | 10 | 9 | 10 | 9 | 10 | 9 |
| Total Expenditure | 9 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 8 |
| Operating Profit | 1 | 0 | -0 | -0 | 1 | -0 | 1 | -0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | -0 | -1 | -1 | 0 | -1 | 0 | -1 | -0 | -0 |
| Provision for Tax | 1 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | 0 | -0 |
| Profit After Tax | -0 | -0 | -1 | -1 | 0 | -1 | 0 | -1 | -0 | 0 |
| Adjustments | 0 | 0 | -0 | 0 | -0 | -0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | -0 | -0 | -1 | -1 | 0 | -1 | 0 | -1 | -0 | 0 |
| Adjusted Earnings Per Share | -0.6 | -0.5 | -0.9 | -0.8 | 0.4 | -1 | 0.2 | -0.7 | -0 | 0 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 19 | 21 | 19 | 23 | 22 | 26 | 19 | 31 | 39 | 38 | 35 | 37 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
| Total Income | 19 | 21 | 19 | 24 | 23 | 26 | 20 | 32 | 39 | 39 | 36 | 38 |
| Total Expenditure | 17 | 18 | 18 | 20 | 20 | 23 | 19 | 26 | 36 | 36 | 35 | 36 |
| Operating Profit | 2 | 3 | 1 | 4 | 3 | 3 | 1 | 6 | 3 | 2 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Exceptional Income / Expenses | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -1 | 1 | -1 | 1 | 0 | 1 | -1 | 4 | 1 | 0 | -1 | -1 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | 0 |
| Profit After Tax | -1 | 1 | -1 | 1 | 0 | 1 | -1 | 4 | 1 | -0 | -1 | -1 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -1 | 1 | -1 | 1 | 0 | 1 | -1 | 4 | 1 | -0 | -1 | -1 |
| Adjusted Earnings Per Share | -1.3 | 0.9 | -1.4 | 2 | 0.1 | 0.7 | -1.7 | 5.3 | 1.2 | -0.6 | -1.8 | -0.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -8% | 4% | 6% | 6% |
| Operating Profit CAGR | -50% | -45% | -20% | -7% |
| PAT CAGR | 0% | NAN% | NAN% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -15% | 8% | 4% | 10% |
| ROE Average | 0% | 0% | 0% | 0% |
| ROCE Average | -5% | 8% | 17% | 18% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | -5 | -5 | -6 | -4 | -4 | -4 | -5 | -1 | 0 | -0 | -2 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
| Other Non-Current Liabilities | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Total Current Liabilities | 12 | 11 | 12 | 12 | 11 | 11 | 12 | 11 | 11 | 11 | 12 |
| Total Liabilities | 19 | 18 | 18 | 19 | 19 | 19 | 19 | 21 | 22 | 23 | 23 |
| Fixed Assets | 15 | 15 | 14 | 15 | 14 | 14 | 13 | 14 | 14 | 15 | 14 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Total Current Assets | 3 | 4 | 4 | 5 | 5 | 5 | 6 | 7 | 8 | 7 | 6 |
| Total Assets | 19 | 18 | 18 | 19 | 19 | 19 | 19 | 21 | 22 | 23 | 23 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 2 | 3 | 3 |
| Cash Flow from Operating Activities | 4 | 2 | 3 | 2 | 2 | 3 | 3 | 4 | 3 | 2 | 2 |
| Cash Flow from Investing Activities | -2 | -0 | -0 | -2 | -1 | -1 | -0 | -2 | -2 | -2 | -1 |
| Cash Flow from Financing Activities | -2 | -1 | -1 | -1 | -1 | -2 | -1 | -2 | -1 | 0 | -2 |
| Net Cash Inflow / Outflow | 0 | 0 | 1 | -1 | 0 | -0 | 2 | 0 | 0 | 0 | -0 |
| Closing Cash & Cash Equivalent | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 3 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -1.3 | 0.88 | -1.42 | 2 | 0.07 | 0.74 | -1.67 | 5.32 | 1.19 | -0.57 | -1.84 |
| CEPS(Rs) | 0.29 | 2.43 | 0.08 | 3.54 | 1.67 | 2.4 | 0.02 | 6.89 | 2.77 | 0.98 | -0.28 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | -7.33 | -6.45 | -7.68 | -5.59 | -5.53 | -4.77 | -6.39 | -1.04 | 0.16 | -0.44 | -2.53 |
| Core EBITDA Margin(%) | 11.34 | 14.68 | 6.82 | 16.25 | 9.43 | 9.51 | 3.27 | 18.3 | 7.75 | 4.47 | -0.59 |
| EBIT Margin(%) | 2.18 | 9.7 | 1.62 | 12.29 | 6.31 | 7.51 | -0.57 | 15.81 | 5.61 | 2.68 | -1.48 |
| Pre Tax Margin(%) | -5.15 | 3.19 | -5.52 | 6.38 | 0.22 | 2.13 | -6.41 | 12.67 | 3.31 | 0.27 | -4.1 |
| PAT Margin (%) | -5.15 | 3.19 | -5.57 | 6.38 | 0.22 | 2.13 | -6.41 | 12.67 | 2.3 | -1.12 | -3.95 |
| Cash Profit Margin (%) | 1.14 | 8.85 | 0.32 | 11.26 | 5.57 | 6.96 | 0.09 | 16.41 | 5.34 | 1.91 | -0.6 |
| ROA(%) | -5.12 | 3.52 | -5.75 | 7.95 | 0.25 | 2.84 | -6.47 | 19.59 | 4.06 | -1.88 | -6.05 |
| ROE(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ROCE(%) | 5.53 | 28.38 | 4.43 | 39.57 | 17.45 | 24.2 | -1.51 | 59.93 | 21.1 | 9.37 | -5.19 |
| Receivable days | 10.82 | 9.6 | 10.68 | 10.44 | 13.02 | 13.36 | 17.3 | 9.94 | 9.87 | 8.67 | 7.53 |
| Inventory Days | 8.42 | 9.8 | 12.39 | 11.04 | 11.74 | 9.33 | 11.82 | 5.66 | 3.88 | 3.96 | 4.38 |
| Payable days | 105.02 | 90.57 | 86.61 | 80.82 | 85.77 | 69.08 | 103.41 | 92.34 | 97.76 | 71.04 | 71.93 |
| PER(x) | 0 | 12.85 | 0 | 9.6 | 180.44 | 10.2 | 0 | 4.35 | 15.56 | 0 | 0 |
| Price/Book(x) | -1.88 | -1.74 | -1.67 | -3.45 | -2.12 | -1.57 | -1.53 | -22.26 | 113.94 | -76.92 | -12.21 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.15 | 0.96 | 1.06 | 1.1 | 0.89 | 0.63 | 0.8 | 0.79 | 0.52 | 0.86 | 0.87 |
| EV/Core EBITDA(x) | 9.61 | 6.27 | 14.14 | 6.39 | 7.67 | 5.08 | 13.54 | 4.02 | 5.95 | 15.06 | 46.65 |
| Net Sales Growth(%) | 5.47 | 8.78 | -7.45 | 23.53 | -4.74 | 15.22 | -24.38 | 61.11 | 23.43 | -1.39 | -8.86 |
| EBIT Growth(%) | -78.04 | 383.56 | -84.57 | 838.91 | -51.11 | 37.23 | -105.72 | 4580.38 | -56.19 | -52.95 | -150.34 |
| PAT Growth(%) | -317.76 | 167.29 | -261.82 | 241.46 | -96.75 | 1028.92 | -327.6 | 418.14 | -77.6 | -148 | -221.41 |
| EPS Growth(%) | -317.75 | 167.29 | -261.82 | 241.46 | -96.75 | 1028.99 | -327.58 | 418.15 | -77.6 | -147.99 | -221.43 |
| Debt/Equity(x) | -2.22 | -2.53 | -2.13 | -2.94 | -2.96 | -3.22 | -2.41 | -13.68 | 87.39 | -34.86 | -5.63 |
| Current Ratio(x) | 0.26 | 0.34 | 0.35 | 0.4 | 0.42 | 0.48 | 0.5 | 0.66 | 0.77 | 0.65 | 0.53 |
| Quick Ratio(x) | 0.22 | 0.27 | 0.3 | 0.33 | 0.36 | 0.41 | 0.46 | 0.62 | 0.73 | 0.61 | 0.5 |
| Interest Cover(x) | 0.3 | 1.49 | 0.23 | 2.08 | 1.04 | 1.4 | -0.1 | 5.04 | 2.43 | 1.11 | -0.56 |
| Total Debt/Mcap(x) | 1.18 | 1.45 | 1.28 | 0.85 | 1.39 | 2.05 | 1.58 | 0.61 | 0.77 | 0.45 | 0.46 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 55.78 | 55.78 | 55.78 | 57.1 | 57.1 | 57.1 | 57.1 | 57.1 | 57.1 | 57.1 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 |
| Public | 44.08 | 44.08 | 44.08 | 42.76 | 42.76 | 42.76 | 42.76 | 42.76 | 42.76 | 42.76 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.42 | 0.42 | 0.42 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.33 | 0.33 | 0.33 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -8% | +4% | +6% | +6% |
| Operating Profit CAGR | -50% | -45% | -20% | -7% |
| PAT CAGR | — | 0% | 0% | — |
| Share Price CAGR | -15% | +8% | +4% | +10% |
| ROE Average | 0% | 0% | 0% | 0% |
| ROCE Average | -5% | +8% | +17% | +18% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 55.78 | 55.78 | 55.78 | 57.1 | 57.1 | 57.1 | 57.1 | 57.1 | 57.1 | 57.1 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 |
| Public | 44.08 | 44.08 | 44.08 | 42.76 | 42.76 | 42.76 | 42.76 | 42.76 | 42.76 | 42.76 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.42 | 0.42 | 0.42 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.33 | 0.33 | 0.33 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.